10-Q 1 kura-20220331.htm 10-Q 10-Q
falseQ1--12-31P5Ytruetrue0001422143P5Y0001422143us-gaap:LeaseholdImprovementsMember2022-03-310001422143us-gaap:USGovernmentAgenciesDebtSecuritiesMembersrt:MaximumMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:FairValueInputsLevel2Memberkura:NonUSGovernmentAndSupranationalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-3100014221432022-01-012022-03-310001422143us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:AccountingStandardsUpdate201602Member2022-01-012022-03-310001422143us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143kura:NonUSGovernmentAndSupranationalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:FairValueInputsLevel2Memberkura:USAgencyBondsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:RetainedEarningsMember2022-01-012022-03-310001422143us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143kura:SanDiegoLeaseMember2020-05-012020-05-310001422143us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001422143us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001422143us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:RetainedEarningsMember2021-01-012021-03-3100014221432021-01-012021-03-310001422143kura:SanDiegoLeaseMember2020-05-310001422143us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001422143us-gaap:CollateralPledgedMember2022-03-310001422143us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:RetainedEarningsMember2021-12-310001422143us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:FairValueInputsLevel2Memberkura:USAgencyBondsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:USTreasurySecuritiesMembersrt:MaximumMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143srt:MaximumMemberkura:NonUSGovernmentAndSupranationalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143kura:USAgencyBondsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001422143us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:RestrictedStockUnitsRSUMember2022-03-310001422143us-gaap:FurnitureAndFixturesMember2021-12-3100014221432021-12-310001422143us-gaap:RetainedEarningsMember2020-12-310001422143us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001422143us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001422143srt:MaximumMemberkura:NonUSGovernmentAndSupranationalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143kura:NonUSGovernmentAndSupranationalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:FairValueInputsLevel2Memberkura:NonUSGovernmentAndSupranationalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143kura:LaboratoryAndComputerEquipmentMember2021-12-310001422143us-gaap:CommonStockMember2021-03-310001422143kura:AtTheMarketFacilityMembersrt:MaximumMemberkura:SVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember2019-03-012019-03-310001422143us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:USTreasurySecuritiesMembersrt:MaximumMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143srt:MaximumMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143kura:BostonLeaseMember2020-03-310001422143us-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:CommercialPaperMembersrt:MaximumMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143kura:OfficeLeaseInBostonMemberus-gaap:LetterOfCreditMember2022-03-3100014221432020-12-310001422143us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001422143us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:CommonStockMember2020-12-310001422143us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001422143kura:BostonLeaseMember2020-03-012020-03-310001422143us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143kura:SanDiegoLeaseMember2022-03-310001422143us-gaap:AdditionalPaidInCapitalMember2022-03-3100014221432022-03-310001422143kura:AtTheMarketFacilityMemberkura:SvbSecuritiesLlcCreditSuisseSecuritiesUsaLlcAndCantorFitzgeraldCoMember2022-01-012022-03-310001422143us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143kura:USAgencyBondsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:USGovernmentAgenciesDebtSecuritiesMembersrt:MaximumMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:LeaseholdImprovementsMember2021-12-310001422143us-gaap:AdditionalPaidInCapitalMember2021-03-310001422143us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:RetainedEarningsMember2021-03-310001422143us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:CommonStockMember2022-03-310001422143us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001422143us-gaap:EmployeeStockOptionMember2022-03-310001422143kura:NonUSGovernmentAndSupranationalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:AccountingStandardsUpdate201602Member2021-01-012021-03-310001422143us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-03-310001422143us-gaap:CommercialPaperMembersrt:MaximumMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143kura:NonUSGovernmentAndSupranationalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:CommonStockMember2021-12-310001422143us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001422143us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001422143us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:AdditionalPaidInCapitalMember2021-12-310001422143kura:AtTheMarketFacilityMemberkura:SvbSecuritiesLlcCreditSuisseSecuritiesUsaLlcAndCantorFitzgeraldCoMembersrt:MaximumMember2022-02-012022-02-280001422143us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001422143us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001422143kura:AtTheMarketFacilityMemberkura:SVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember2022-01-012022-03-310001422143us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001422143us-gaap:AdditionalPaidInCapitalMember2020-12-310001422143us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001422143us-gaap:CommonStockMember2021-01-012021-03-310001422143us-gaap:CommonStockMember2022-01-012022-03-3100014221432021-03-310001422143us-gaap:FurnitureAndFixturesMember2022-03-3100014221432022-04-290001422143kura:SanDiegoLeaseForLabAndOfficeSpaceMember2022-03-310001422143us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001422143kura:LaboratoryAndComputerEquipmentMember2022-03-310001422143us-gaap:RetainedEarningsMember2022-03-310001422143us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001422143srt:MaximumMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-31xbrli:purexbrli:sharesiso4217:USDxbrli:shareskura:Securityiso4217:USD

say

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission File Number: 001-37620

 

 

KURA ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

61-1547851

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

 

 

12730 High Bluff Drive, Suite 400, San Diego, CA

 

92130

(Address of principal executive offices)

 

(Zip Code)

(858) 500-8800

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

KURA

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

As of the close of business on April 29, 2022, the registrant had 66,636,105 shares of Common Stock, $0.0001 par value, outstanding.

 

 

 

 


KURA ONCOLOGY, INC.

TABLE OF CONTENTS

 

PART I. FINANCIAL INFORMATION

 

 

 

 

 

Item 1. Condensed Financial Statements (unaudited)

 

 

 

 

 

Condensed Balance Sheets − As of March 31, 2022 (unaudited) and December 31, 2021

1

 

 

 

 

Condensed Statements of Operations and Comprehensive Loss – Three months ended March 31, 2022 and 2021 (unaudited)

2

 

 

 

 

Condensed Statements of Stockholders’ Equity – Three months ended March 31, 2022 and 2021 (unaudited)

3

 

 

 

 

Condensed Statements of Cash Flows – Three Months Ended March 31, 2022 and 2021 (unaudited)

4

 

 

 

 

Notes to Condensed Financial Statements (unaudited)

5

 

 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

11

 

 

 

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

18

 

 

 

 

Item 4. Controls and Procedures

18

 

 

PART II. OTHER INFORMATION

 

 

 

 

 

Item 1. Legal Proceedings

19

 

 

 

 

Item 1A. Risk Factors

19

 

 

 

 

Item 6. Exhibits

62

 

 

Signatures

 

 

 

 

 


PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

KURA ONCOLOGY, INC.

Condensed Balance Sheets

(In thousands, except par value data)

 

 

 

 

March 31,
2022

 

 

December 31,
2021

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

33,832

 

 

$

90,672

 

Short-term investments

 

 

446,243

 

 

 

427,288

 

Prepaid expenses and other current assets

 

 

6,959

 

 

 

4,329

 

Total current assets

 

 

487,034

 

 

 

522,289

 

Property and equipment, net

 

 

2,567

 

 

 

2,673

 

Restricted cash

 

 

210

 

 

 

210

 

Operating lease right-of-use assets

 

 

5,149

 

 

 

5,573

 

Other long-term assets

 

 

3,625

 

 

 

3,306

 

Total assets

 

$

498,585

 

 

$

534,051

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

1,337

 

 

$

3,236

 

Accrued expenses

 

 

14,112

 

 

 

16,956

 

Current operating lease liabilities

 

 

2,276

 

 

 

2,263

 

Total current liabilities

 

 

17,725

 

 

 

22,455

 

Long-term operating lease liabilities

 

 

4,114

 

 

 

4,612

 

Other long-term liabilities

 

 

496

 

 

 

375

 

Total liabilities

 

 

22,335

 

 

 

27,442

 

Stockholders' equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares
     issued and outstanding

 

 

 

 

 

 

Common stock, $0.0001 par value; 200,000 shares authorized;
     
66,636 and 66,572 shares issued and outstanding as of
     March 31, 2022 and December 31, 2021, respectively

 

 

7

 

 

 

7

 

Additional paid-in capital

 

 

948,312

 

 

 

941,359

 

Accumulated other comprehensive loss

 

 

(6,648

)

 

 

(1,789

)

Accumulated deficit

 

 

(465,421

)

 

 

(432,968

)

Total stockholders' equity

 

 

476,250

 

 

 

506,609

 

Total liabilities and stockholders' equity

 

$

498,585

 

 

$

534,051

 

 

See accompanying notes to unaudited condensed financial statements.

1


KURA ONCOLOGY, INC.

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2022

 

 

2021

 

Operating Expenses:

 

 

 

 

 

 

Research and development

 

$

20,913

 

 

$

20,324

 

General and administrative

 

 

11,869

 

 

 

10,572

 

Total operating expenses

 

 

32,782

 

 

 

30,896

 

Other Income (Expense):

 

 

 

 

 

 

Interest and other income, net

 

 

329

 

 

 

310

 

Interest expense

 

 

 

 

 

(108

)

Total other income, net

 

 

329

 

 

 

202

 

Net Loss

 

$

(32,453

)

 

$

(30,694

)

 

 

 

 

 

 

 

Net loss per share, basic and diluted

 

$

(0.49

)

 

$

(0.46

)

Weighted average number of shares used in computing
     net loss per share, basic and diluted

 

 

66,607

 

 

 

66,218

 

 

 

 

 

 

 

 

Comprehensive Loss:

 

 

 

 

 

 

Net loss

 

$

(32,453

)

 

$

(30,694

)

Other comprehensive loss:

 

 

 

 

 

 

Unrealized loss on marketable securities and
     foreign currency

 

 

(4,859

)

 

 

(128

)

Comprehensive Loss

 

$

(37,312

)

 

$

(30,822

)

 

See accompanying notes to unaudited condensed financial statements.

 

2


KURA ONCOLOGY, INC.

Condensed Statements of Stockholders’ Equity

(In thousands)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

Total

 

 

Common Stock

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders'

 

 

Shares

 

 

Par Value

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2021

 

66,572

 

 

$

7

 

 

$

941,359

 

 

$

(1,789

)

 

$

(432,968

)

 

$

506,609

 

Share-based compensation expense

 

 

 

 

 

 

 

6,650

 

 

 

 

 

 

 

 

 

6,650

 

Issuance of common stock under equity incentive plan

 

64

 

 

 

 

 

 

303

 

 

 

 

 

 

 

 

 

303

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

(4,859

)

 

 

 

 

 

(4,859

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

(32,453

)

 

 

(32,453

)

Balance at March 31, 2022

 

66,636

 

 

$

7

 

 

$

948,312

 

 

$

(6,648

)

 

$

(465,421

)

 

$

476,250

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

Total

 

 

Common Stock

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders'

 

 

Shares

 

 

Par Value

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2020

 

66,194

 

 

$

7

 

 

$

913,354

 

 

$

46

 

 

$

(302,502

)

 

$

610,905

 

Share-based compensation expense

 

 

 

 

 

 

 

5,075

 

 

 

 

 

 

 

 

 

5,075

 

Issuance of common stock under equity incentive plan

 

69

 

 

 

 

 

 

829

 

 

 

 

 

 

 

 

 

829

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

(128

)

 

 

 

 

 

(128

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

(30,694

)

 

 

(30,694

)

Balance at March 31, 2021

 

66,263

 

 

$

7

 

 

$

919,258

 

 

$

(82

)

 

$

(333,196

)

 

$

585,987

 

 

See accompanying notes to unaudited condensed financial statements.

 

3


KURA ONCOLOGY, INC.

Condensed Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2022

 

 

2021

 

Operating Activities

 

 

 

 

 

 

Net loss

 

$

(32,453

)

 

$

(30,694

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Share-based compensation expense

 

 

6,650

 

 

 

5,075

 

Depreciation expense

 

 

177

 

 

 

108

 

Amortization of premium and accretion of discounts on
     marketable securities, net

 

 

1,100

 

 

 

850

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

(2,630

)

 

 

(2,860

)

Other long-term assets

 

 

105

 

 

 

410

 

Accounts payable and accrued expenses

 

 

(5,251

)

 

 

(1,452

)

Other long-term liabilities

 

 

121

 

 

 

46

 

Net cash used in operating activities

 

 

(32,181

)

 

 

(28,517

)

 

 

 

 

 

 

 

Investing Activities

 

 

 

 

 

 

Purchases of marketable securities

 

 

(51,400

)

 

 

(223,158

)

Maturities of marketable securities

 

 

26,487

 

 

 

36,969

 

Purchases of property and equipment

 

 

(49

)

 

 

(31

)

Net cash used in investing activities

 

 

(24,962

)

 

 

(186,220

)

 

 

 

 

 

 

 

Financing Activities

 

 

 

 

 

 

Proceeds from issuance of stock under equity incentive plan

 

 

303

 

 

 

829

 

Repayment of long-term debt

 

 

 

 

 

(750

)

Net cash provided by financing activities

 

 

303

 

 

 

79

 

Net decrease in cash, cash equivalents and restricted cash

 

 

(56,840

)

 

 

(214,658

)

Cash, cash equivalents and restricted cash at beginning of period

 

 

90,882

 

 

 

325,703

 

Cash, cash equivalents and restricted cash at end of period

 

$

34,042

 

 

$

111,045

 

See accompanying notes to unaudited condensed financial statements.

 

4


KURA ONCOLOGY, INC.

Notes to Unaudited Condensed Financial Statements

 

1. Organization and Basis of Presentation

The Company

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule product candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes, and we intend to pair them with molecular or cellular diagnostics to identify those patients most likely to respond to treatment. We plan to advance our product candidates through a combination of internal development and strategic partnerships while maintaining significant development and commercial rights.

References in these Notes to Unaudited Condensed Financial Statements to the “Company,” “we,” “our” or “us,” refer to Kura Oncology, Inc.

Basis of Presentation

The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the Securities and Exchange Commission on February 24, 2022, from which we derived our balance sheet as of December 31, 2021. The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying unaudited condensed financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited condensed financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

The preparation of the unaudited condensed financial statements in accordance with GAAP requires our management to make estimates and assumptions that affect the amounts reported on our unaudited condensed financial statements and accompanying notes. The amounts reported could differ under different estimates and assumptions. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.

The extent to which the COVID-19 pandemic has impacted and may continue to impact our business will depend on future developments, which are highly uncertain and cannot be predicted with any confidence, such as the duration and severity of the COVID-19 pandemic, steps required or mandated by governments to mitigate the impact of COVID-19 or the effectiveness of actions to prevent, contain and treat COVID-19, particularly in the geographies where we, our third-party manufacturers, contract research organizations or current and planned clinical trial sites operate. We cannot presently predict the scope and severity of any potential business disruptions, interruptions or shutdowns. If we or any of the third parties with whom we engage, however, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business and our results of operations and financial condition.

5


2. Summary of Significant Accounting Policies

Reclassifications

Certain prior period balances have been reclassified to conform to the current period presentation.

Restricted Cash

Under the terms of an office lease entered into in March 2020, we are required to maintain a standby letter of credit during the term of the lease. As of March 31, 2022, restricted cash of $0.2 million was pledged as collateral for the letter of credit.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed balance sheets that sum to the total of the amounts shown in the unaudited condensed statements of cash flows, in thousands:

 

 

March 31, 2022

 

 

December 31, 2021

 

 

March 31, 2021

 

 

December 31, 2020

 

Cash and cash equivalents

 

$

33,832

 

 

$

90,672

 

 

$

110,835

 

 

$

325,493

 

Restricted cash

 

 

210

 

 

 

210

 

 

 

210

 

 

 

210

 

Total

 

$

34,042

 

 

$

90,882

 

 

$

111,045

 

 

$

325,703

 

 

Allowance for Credit Losses

For available-for-sale securities in an unrealized loss position, we first assess whether we intend to sell, or if it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive income (loss) on the unaudited condensed statements of operations and comprehensive loss.

We elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of our available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded within prepaid expenses and other current assets on our unaudited condensed balance sheets. Our accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which we consider to be in the period in which we determine the accrued interest will not be collected by us.

Concentration of Credit Risk

Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. We maintain deposits in federally insured financial institutions in excess of federally insured limits. We have established guidelines to limit our exposure to credit risk by placing investments with high credit quality financial institutions, diversifying our investment portfolio and placing investments with maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.

Net Loss per Share

Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury-stock method. As we have reported net loss for the three months ended March 31, 2022 and 2021, dilutive net loss per common share is the same as basic net loss per common share for those periods. Common stock equivalents outstanding are comprised of stock options, restricted stock units, a warrant and employee stock purchase plan rights and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. Common stock equivalents outstanding at March 31, 2022 and 2021 totaling approximately 9,501,000 and

6


6,834,000, respectively, were excluded from the computation of dilutive weighted-average shares outstanding because their effect would be anti-dilutive.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. We have evaluated recently issued accounting pronouncements and, based on our preliminary assessment, we do not believe any will have a material impact on our unaudited condensed financial statements or related footnote disclosures.

3. Investments

We invest in available-for-sale securities consisting of money market funds, corporate debt securities, U.S. Treasury securities, commercial paper, non-U.S. government debt securities, supranational debt securities and U.S. Agency bonds. Available-for-sale securities are classified as either cash and cash equivalents or short-term investments on our unaudited condensed balance sheets.

The following tables summarize, by major security type, our short-term investments that are measured at fair value on a recurring basis, in thousands:

 

 

 

 

March 31, 2022

 

 

Maturities
(years)

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair Value

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

1 or less

 

$

29,245

 

 

$

 

 

$

 

 

$

29,245

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

3 or less

 

 

192,065

 

 

 

 

 

 

(3,366

)

 

 

188,699

 

U.S. Treasury securities

3 or less

 

 

170,309

 

 

 

2

 

 

 

(2,372

)

 

 

167,939

 

Commercial paper

1 or less

 

 

58,427

 

 

 

 

 

 

 

 

 

58,427

 

Non-U.S. government and supranational debt securities

3 or less

 

 

23,094

 

 

 

 

 

 

(719

)

 

 

22,375

 

U.S. Agency bonds

2 or less

 

 

8,995

 

 

 

 

 

 

(192

)

 

 

8,803

 

Total short-term investments

 

 

 

452,890

 

 

 

2

 

 

 

(6,649

)

 

 

446,243

 

Total

 

 

$

482,135

 

 

$

2

 

 

$

(6,649

)

 

$

475,488

 

 

 

 

 

December 31, 2021

 

 

Maturities
(years)

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair Value

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

1 or less

 

$

79,895

 

 

$

 

 

$

 

 

$

79,895

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

3 or less

 

 

208,064

 

 

 

 

 

 

(892

)

 

 

207,172

 

U.S. Treasury securities

3 or less

 

 

135,452

 

 

 

 

 

 

(619

)

 

 

134,833

 

Commercial paper

1 or less

 

 

53,439

 

 

 

 

 

 

 

 

 

53,439

 

Non-U.S. government and supranational debt securities

3 or less

 

 

23,122

 

 

 

 

 

 

(214

)

 

 

22,908

 

U.S. Agency bonds

2 or less

 

 

8,994

 

 

 

 

 

 

(58

)

 

 

8,936

 

Total short-term investments

 

 

 

429,071

 

 

 

 

 

 

(1,783

)

 

 

427,288

 

Total

 

 

$

508,966

 

 

$

 

 

$

(1,783

)

 

$

507,183

 

Short-term investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities

7


to fund our operations, as necessary. As of March 31, 2022 and December 31, 2021, short-term investments of $292.0 million and $246.9 million, respectively, had maturities less than one year, and short-term investments of $154.2 million and $180.4 million, respectively, had maturities between one to three years. We had no realized gains or losses for the three months ended March 31, 2022 and 2021.

As of March 31, 2022, 36 available-for-sale securities with a fair market value of $366.8 million were in gross unrealized loss positions, none of which were in a continuous unrealized loss position for greater than 12 months. We do not intend to sell these available-for-sale securities, and it is not more likely than not that we will be required to sell these securities prior to recovery of their amortized cost basis. Based on our review of these available-for-sale securities, the unrealized losses at March 31, 2022 were primarily due to changes in interest rates and not due to increased credit risks associated with specific securities. We have no allowance for credit losses as of March 31, 2022 and December 31, 2021. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive (income) loss.

Accrued interest receivable on available-for-sale securities were $1.6 million and $1.4 million at March 31, 2022 and December 31, 2021, respectively. We have not written off any accrued interest receivables for the three months ended March 31, 2022 and 2021.

4. Fair Value Measurements

As of March 31, 2022 and December 31, 2021, we had cash equivalents and short-term investments measured at fair value on a recurring basis.

Available-for-sale securities consist of U.S. Treasury securities, which are measured at fair value using Level 1 inputs, and corporate debt securities, commercial paper, non-U.S. government debt securities, supranational debt securities and U.S. Agency bonds which are measured at fair value using Level 2 inputs. We determine the fair value of Level 2 related securities with the aid of valuations provided by third parties using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. We validate the fair values of Level 2 financial instruments by comparing these fair values to a third-party pricing source.

The following tables summarize, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy, in thousands:

 

 

 

March 31, 2022

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

Money market funds

 

$

29,245

 

 

$

29,245

 

 

$

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

188,699

 

 

 

 

 

188,699

 

U.S. Treasury securities

 

 

167,939

 

 

 

167,939

 

 

 

 

Commercial paper

 

 

58,427

 

 

 

 

 

58,427

 

Non-U.S. government and supranational debt securities

 

 

22,375

 

 

 

 

 

 

22,375

 

U.S. Agency bonds

 

 

8,803

 

 

 

 

 

 

8,803

 

Total short-term investments

 

 

446,243

 

 

 

167,939

 

 

 

278,304

 

Total

 

$

475,488

 

 

$

197,184

 

 

$

278,304

 

 

8


 

 

December 31, 2021

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

Money market funds

 

$

79,895

 

 

$

79,895

 

 

$